HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reels In Golden Caviar For Fishy Skin-Care Claims

This article was originally published in The Rose Sheet

Executive Summary

Skin-lightening claims appear to be on FDA's radar as it continues its crackdown on overreaching cosmetic marketing, issuing a warning letter to Golden Caviar Skin Care for statements promoting a whitening serum and cream, among other offerings. The company's Caviar Lifting and Firming Serum with Zinc also is an unapproved drug, based on claimed benefits including wound healing and acne relief, the agency says.

You may also be interested in...

FDA Warns Pharmagel, Updates Webpage On Drug-Claim Violations

Pharmagel's name and billing as "pharmaceutical grade anti-aging skin care" may have drawn FDA's attention, but benefits cited in the agency's warning letter – including collagen- and elastic-building claims – are consistent with FDA's enforcement action against other companies so far in 2015.

FDA Warning To L’Oreal Creates Uncertainty For Anti-Redness, Dark Spot Treatments

In a Feb. 12 warning letter, just the descriptors for two L’Oreal/La Roche-Posay products – a “Localized Redness Intensive Serum” and “Concentrated Dark Spot Correcting Serum” – are cited by FDA as evidence that the products are intended for use as drugs. The warning raises questions about the viability of those categories for cosmetics firms intent on staying off FDA’s radar.

How Not To Cross FTC: Attorneys Offer Advice For Cosmeceutical Marketers

Claims for cosmeceuticals referred by the National Advertising Division go to the same place on the Federal Trade Commission's list of priorities as other disputed claims - straight to the top

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts